009420 — Hanall Biopharma Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapMomentum Trap

Annual income statement for Hanall Biopharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	101,594	109,995	134,910	138,944	155,185
Cost of Revenue
Gross Profit	60,333	61,971	75,172	73,306	80,858
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	91,495	108,490	132,728	138,659	156,359
Operating Profit	10,100	1,506	2,182	284	-1,175
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	8,702	1,929	3,203	-183	-6,180
Provision for Income Taxes
Net Income After Taxes	8,896	251	3,509	-1,805	-5,559
Net Income Before Extraordinary Items
Net Income	8,896	251	3,509	-1,805	-5,559
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	8,896	251	3,509	-1,805	-5,559
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	187	4.73	69.7	-30.5	-106
Dividends per Share